Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fulvestrant + GTAEXS617 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 31 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
| GTAEXS617 | GTAEXS 617|GTAEXS-617 | CDK7 Inhibitor 16 | GTAEXS617 inhibits CDK7, potentially resulting in cell cycle arrest, increased apoptosis, and reduced proliferation of tumor cells, and decreased tumor growth (Cancer Res (2022) 82 (12_Supplement): 3930). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05985655 | Phase Ib/II | GTAEXS617 Fulvestrant + GTAEXS617 Bevacizumab + GTAEXS617 + Paclitaxel | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (ELUCIDATE) | Recruiting | USA | GBR | BEL | 0 |